|
Parameter
|
Patients above cut-off (%)
|
Patients below cut-off (%)
|
p values
|
Number of analyzed patients
|
Hazard ratios
|
|---|
|
Deterioration ≥ 10%
|
No deterioration
|
Deterioration ≥ 10%
|
No deterioration
|
|---|
|
Anti-CXCR3 antibodies
|
|
FVC (%)
|
25.0
|
75.0
|
59.3
|
40.7
|
≤ 0.01
|
59
|
0.32
|
|
FEV1 (%)
|
23.5
|
76.5
|
71.1
|
28.9
|
≤ 0.001
|
72
|
0.22
|
|
DLCO-SB (%)
|
36.4
|
63.6
|
63.6
|
36.4
|
≤ 0.05
|
55
|
0.47
|
|
DLCO/VA (%)
|
42.4
|
57.6
|
70.4
|
29.6
|
≤ 0.05
|
60
|
0.38
|
|
Anti-CXCR4 antibodies
|
|
FVC (%)
|
22.2
|
77.8
|
70.0
|
30.0
|
≤ 0.001
|
47
|
0.2
|
|
FEV1 (%)
|
33.3
|
66.7
|
78.6
|
21.4
|
≤ 0.001
|
61
|
0.27
|
|
TLC (%)
|
33.3
|
66.7
|
64.7
|
35.3
|
≤ 0.05
|
44
|
0.33
|
|
DLCO-SB (%)
|
43.3
|
56.7
|
75.0
|
25.0
|
≤ 0.05
|
46
|
0.46
|
|
DLCO/VA (%)
|
39.4
|
60.6
|
82.4
|
17.6
|
≤ 0.001
|
50
|
0.24
|
- Patients with antibody levels above and below cut-off, with and without deterioration in forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), total lung capacity (TLC), the diffusing capacity for carbon monoxide (DLCO) measured by a single breath (DLCO-SB), and DLCO/VA within 3 years, p values (log-rank test) as well as number of analyzed patients are shown
- Hazard ratios derived from the Cox proportional hazards model highlight the relationship between deterioration in lung function parameters and anti-CXCR3/anti-CXCR4 antibody levels
